Juan Manuel Igea Aznar

Juan Manuel Igea Aznar

Auto-generated profile, based on publicly available information

Juan Manuel Igea Aznar

Clínica Alergoasma, Salamanca, Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2026 in Journal of Asthma and Allergy
Verified
Journal Article
Open access
PDF file
JDJavier Dominguez-Ortega
Javier Dominguez-Ortega
GLGabriela Leon-Zambrana
Gabriela Leon-Zambrana
José Antonio CañasJosé Antonio Cañas
José Antonio Cañas
IGIsmael García-Moguel
Ismael García-Moguel
JIJuan Manuel Igea
Juan Manuel Igea
Victoria Del PozoVictoria Del Pozo
Victoria Del Pozo
Background: Accurate inflammatory phenotyping in asthma remains challenging. Nasal cytology has emerged as a potential non-invasive tool to assess airway inflammation in asthma. However, its relationship with lower airway inflammation and systemic biomarkers remains unclear, particularly in severe asthma (SA). Objective: To evaluate whether a multi-compartment approach could improve the characterisation of type 2 inflammation and the relationship between nasal cytology, induced sputum, and systemic inflammatory biomarkers in patients with severe asthma. Methods: In this cross-sectional exploratory BRISA study, twenty-two patients with SA underwent nasal cytology by mucosal scraping, induced sputum analysis, and serum biomarker assessment (periostin, eosinophil cationic protein, thymic stromal lymphopoietin, dipeptidyl peptidase-4, and total IgE). Patients were stratified according to blood eosinophil count (BEC < 300 vs ≥ 300 cells/μL). Correlations between compartments and associations with clinical and inflammatory variables were analysed. Results: Higher blood eosinophil counts were associated with worse lung function, increased exacerbations, and higher serum periostin levels. Valid induced sputum samples were obtained in 16 patients: 7 eosinophilic, 3 neutrophilic, 2 mixed eosinophilic-neutrophilic and 4 paucigranulocytic. Nasal cytology predominantly showed limited agreement with induced sputum inflammatory phenotypes. Serum TSLP, DPP4, and IgE also showed an upward trend in patients with higher blood eosinophil counts, although these differences were not statistically significant. Correlation analysis demonstrated a significant positive association between sputum and blood eosinophils, as well as between blood eosinophils and serum periostin. A strong positive correlation was also observed between serum eotaxin and TSLP. Conclusion: Nasal cytology alone cannot replace induced sputum for inflammatory phenotyping in SA, although it may provide complementary information on upper airway inflammation. Among the evaluated systemic biomarkers, periostin emerged as the most consistent marker associated with blood eosinophilia, while other biomarkers showed only non-significant trends. Further studies are needed to validate the role of combined biomarkers in predicting airway inflammation.

31 October 2026 in Pulmonary Therapy
Verified
Journal Article
Open access
PDF file
JBJohn Blakey
John Blakey
PPPaul Pfeffer
Paul Pfeffer
CDChristian Domingo
Christian Domingo
JAJuan Manuel Igea Aznar
Juan Manuel Igea Aznar
MVManish Verma
Manish Verma
Introduction Inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combinations are a cornerstone of moderate asthma management that have been approved to treat asthma on the basis of results from randomized controlled trials (RCTs). However, efficacy observed in RCTs does not necessarily translate directly into effectiveness, partly because of lower adherence or persistence and less intensive follow-up structures in routine clinical practice. This has driven interest in real-world evidence (RWE) studies and pragmatic RCTs as sources of evidence complementary to conventional RCTs. We aimed to assess how considering multiple study types could enhance our understanding of ICS/LABA therapy in asthma management. Methods We undertook a targeted literature search of PubMed/MEDLINE of RCTs (conventional and pragmatic) and RWE studies evaluating ICS/LABA therapies in patients with moderate asthma through a structured screening approach. Results Twenty two publications were selected for descriptive comparison. Similar results for ICS/LABA therapies were reported across studies, supporting the generalizability of conventional RCT findings to routine clinical practice. Reported severe exacerbation rates per patient per year (PPPY) were approximately 0.14–0.31 PPPY in conventional RCTs, 0.12–0.47 PPPY in pragmatic RCTs, and overall exacerbation rates 0.07–0.18 in RWE studies, with lower rates reported for ICS/LABA interventions than comparator. Across studies, approximately half of patients reported improvements in asthma control following ICS/LABA treatment. Conventional RCTs reported high treatment persistence and generally higher treatment adherence than pragmatic RCTs or RWE studies; however, the perceived impacts of adherence on treatment effects were mixed between studies. Where reported, lung function data indicated improvements following ICS/LABA treatment, although RWE data were limited. Conclusion Our findings support the view that conventional RCTs, pragmatic RCTs, and RWE studies represent complementary components of a unified evidence continuum that should be considered together to optimize patient care. Integrating evidence across this continuum provides a more comprehensive understanding of ICS/LABA therapy and may better inform personalized treatment decisions in asthma.